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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the efficacy and safety of alternative primaquine regimens for radical cure ofP. vivax malaria compared to the standard 14 days
of primaquine 0.25 mg/kg/day.
B A C K G R O U N D
Malaria is a potentially life-threatening disease caused by the Plas-
modium parasite, which is transmitted by the bite of an infected
female Anopheles mosquito. There are five species of Plasmod-
ium malaria parasites that can cause malaria disease in humans,
of these, Plasmodium vivax and Plasmodium falciparum are gen-
erally recognized as the most significant threat to human health
(WHO2016a). In 2015, there were an estimated 212million cases
of malaria worldwide, with 429,000 attributable deaths (WHO
2016b). By 2030, the World Health Organization (WHO) aims
to reduce malaria case load and mortality by at least 90% (WHO
2016a).
Historically, P. vivax infection was thought to be a milder form of
malariawithminimalmorbidity, with the greater focus for research
on P. falciparum, because of the high number of deaths it causes
(Bassat 2016). In recent years the morbidity and mortality of P. vi-
vax have been shown to have been underestimated, with evidence
of direct fatality and contribution to mortality in patients who
have other co-morbidities, such as malnutrition, human immun-
odeficiency virus (HIV), or co-existing infections (Baird 2013;
Bhattacharjee 2013;Rizvi 2013; Singh 2013; Battle 2014;Douglas
2014; Kochar 2014; Arévalo-Herrera 2015; Baird 2015b). Re-
peated P. vivax infections through childhood and adulthood also
affect personal well-being, development, and education and can
thus negatively impact economic development, both for the indi-
vidual and the community (Mendis 2001).P. vivaxmalaria in preg-
nancy is associated with maternal anaemia, spontaneous abortion,
stillbirth, and lowbirthweight, with especially poor pregnancy out-
comes for women with severe infection (McGready 2012; Rijken
2012; Brutus 2013).
Description of the condition
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P. vivax infection caused an estimated 13.8million cases of malaria
in 2015 and is responsible for almost half of the global cases of
malaria outside of Sub-Saharan Africa (WHO 2015c). The geo-
graphical distribution ofP. vivax malaria is more widespread than
any of the other forms of human malaria - around 35% of the
world’s population is thought to be at risk, with two-thirds of cases
occurring in South-East Asia (WHO 2015a). Co-infection with P.
falciparum is also common inmany regions (Kumar 2007;Mueller
2009). As malaria control accelerates, the P. vivax proportion in
co-endemic areas tends to rise compared to that of P. falciparum,
which highlights the importance and challenge of this infection
(John 2012).
P. vivax is also important as many countries progress towards
malaria elimination, as it is increasingly recognized as a potential
roadblock to eradication (Cibulskis 2015; Bassat 2016). Despite a
reduction in the number of cases of P. vivax malaria over the past
20 years, it has several characteristics that enable it to evade con-
trol (Newby 2016). The early appearance of gametocytes in the
blood, often prior to symptoms of malaria, increases the chance
of onward transmission by mosquitoes (WHO 2015a). P. vivax
differs to P. falciparum in that as well as having a blood stage
schizontal infection, hypnozoites develop in the liver that can be
dormant for weeks to months before developing into an infec-
tion (Llanos-Cuentas 2014). It is not known what triggers these
relapses. There is difficultly in distinguishing between relapse, re-
crudescence (subpar treatment of the initial blood stage infection),
and reinfection (new infection with P. vivax) (Betuela 2014). A
study in Papua New Guinea suggested that relapses cause four-
fifths of P. vivax infections, so are important in sustaining trans-
mission (Robinson 2015). Parasites show high genetic diversity,
even in countries that are at malaria elimination stage, where you
would expect reduced transmission to result in reduced diversity
(Koepfli 2015). P. vivax is likely underestimated worldwide as the
dormant liver stage is not detected in routine surveys (Gething
2012). Submicroscopic infections (asymptomatic infection reser-
voirs) may also lead to underdiagnosis or misdiagnosis. A system-
atic review showed that across all study sites the polymerase chain
reaction (PCR) prevalence of P. vivaxwas significantly higher than
that identified by light microscopy (Cheng 2015). The effect that
this may have on P. vivax malaria studies is unclear. There are dif-
ferent strains of P. vivax, which have varying relapse patterns, and
this can further complicate matters (White 2016). The Chesson,
or tropical, strain is commonly found in South East Asia, Oceania,
and parts of the Indian subcontinent and has the shortest relapse
interval of about three weeks (if untreated), while the temperate
strain may relapse after months (John 2012).
Currently primaquine, an 8-aminoquinoline, is the only drug
available on the market for treating the hypnozoite stage of infec-
tion (Ashley 2014). One of the main barriers in P. vivax treatment
is the reluctance to use primaquine due to it causing haemolysis
in patients with glucose-6-phosphate-dehydrogenase (G6PD) de-
ficiency. G6PD deficiency is the commonest enzyme deficiency
worldwide and affects red blood cells, by leading to their premature
lysis (Nkhoma 2009). G6PD deficiency is common in countries
where P. vivax malaria is endemic, with an estimated population
prevalence of 8% (Howes 2012). Within G6PD deficiency there
are differing phenotypes,meaning some peoplemay bemildly sen-
sitive to primaquine, while others may be very sensitive and expe-
rience life threatening haemolysis (Baird 2015a), which explains
the varying responses to primaquine. In many countries where P.
vivax is pre-dominant, locally available testing for G6PD is not
available (Baird 2015b). A newer alternative, tafenoquine, another
8-aminoquinoline, has completed phase III trials and is on track
for submission to the Food and Drug Administration (FDA) in
2017 (MMV 2016). Tafenoquine has shown promise in reducing
relapses, but there are increased safety concerns in patients with
undiagnosed G6PD deficiency compared to primaquine, due to
its longer half-life (Rajapakse 2015).
Description of the intervention
People with P. vivax malaria require treatment with a blood stage
antimalarial drug to treat the schizont infection, and a drug to
treat the hypnozoite stage (radical cure). The WHO recommends
treatment with either chloroquine or an artemisinin-based com-
bination therapy (ACT) for the blood-stage infection, followed by
treatment with 0.25 to 0.5 mg/kg primaquine for 14 days (WHO
2015b). ACTs and chloroquine have been shown to be effective
and comparable in treating the blood stage infection of P. vivax
malaria (Gogtay 2013). A previous Cochrane Review showed that
primaquine regimes of five days or fewer had similar relapse rates
to placebo or no primaquine. Of the comparisons included in the
systematic review, a regime of 0.25 mg/kg (15 mg) a day of pri-
maquine for 14 days had the lowest relapse rates of P. vivax infec-
tion (Galappaththy 2013). There were no trials at that time that
compared higher doses of primaquine at 14 or seven days.
Primaquine was first made available to American soldiers in the
1950s (Baird 2004). Its mechanism and metabolism is not widely
understood, but it has a broad spectrumof activity against thePlas-
modium parasite. As well as preventing relapse of P. vivax malaria
by targeting the latent and developing hypnozoites in the liver,
it is also used in malaria prophylaxis (Baird 2003). It is absorbed
from the gastrointestinal tract, has a half life of about four to nine
hours, and crosses the placenta in pregnancy (Baird 2004). New
advancements in studying P. vivax in humanized mice may lead to
a greater understanding of themechanism of action of primaquine
(Mikolajczak 2015).
Adverse effects of primaquine include
production of methaemoglobin, an oxidated state of haemoglo-
bin which cannot transport oxygen to tissues. Methaemoglobi-
naemia (an abnormal build-up of methaemoglobin) can result in
cyanosis when levels exceed 10% of the usual haemoglobin level
(Vale 2009). As described above, primaquine causes haemolysis in
people with G6PD deficiency, which leads to severe intravascular
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haemolysis and anaemia (Ashley 2014). When taken on an empty
stomach it can cause abdominal pain and gastrointestinal upset
(Vale 2009). Primaquine cannot be given in pregnancy or early
infancy as the G6PD status of the baby is unknown and there
would be risk of haemolysis and possible termination if the foetus
was G6PD-deficient. There is currently debate about whether the
levels of primaquine in breast milk would be sufficient to cause
haemolysis in a G6PD-deficient baby, but it is not recommended
at this time.
How the intervention might work
TheWHOadvises that 0.25mg to0.5mg/kg of primaquine for 14
days should be used for radical cure of P. vivax malaria in patients
over six months old, excluding people with G6PD deficiency and
patients who are pregnant or breastfeeding (WHO 2015b). There
has been suggestion of failure of the 0.25 mg/kg/14-day dosing
regimen of primaquine for the Chesson strain of P. vivax, which is
what was behind the suggestion of the increased dosing of 0.5 mg/
kg/day. In the last review, Galappaththy 2013, there were no trials
found which compared higher doses of primaquine to the 14-day
regime. The WHO recommends a weekly dose of 0.75 mg/kg for
eight weeks for patients with G6PD deficiency but the evidence
for this is low quality as there are few high-quality trials (WHO
2015b).
The 14-day course of primaquine, which can lead to adherence
issues in patients, as well as safety concerns about haemolysis in
places where G6PD testing is not available, means that shorter
courses of primaquine are desirable. Failure to treat the hypnozoite
stage of P. vivax malaria leads to repeated relapses, morbidity, and
persistent infection. The logic framework for developing effica-
cious and safe treatment regimes for P. vivax is illustrated in Figure
1.
Figure 1. Logic framework: treatment outcome pathways in Plasmodium vivax liver hypnozoite infection
It has long been suggested that it may be the total dose of pri-
maquine that is important in treatment of the hypnozoite stage
rather than the length of the course (Schmidt 1977). If a higher
dose of primaquine could be administered safely over a shorter
period of time, this may improve adherence rates, thus reducing
relapse rates and morbidity and mortality resulting from P. vi-
vax infection. There are small trials from the 1970s that suggest
that shorter, higher dose regimes were as efficacious as the 14-day
courses (Clyde 1977), and there is also evidence of similar efficacy
(Saint-Yves 1977). At the time of the last review (Galappaththy
2013) there were no recent large high-quality trials that had in-
vestigated the use of higher doses given over seven days. We plan
to include any such trials in this Cochrane Review.
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Why it is important to do this review
The use of primaquine for radical cure of P. vivax malaria contin-
ues to pose a therapeutic dilemma for healthcare providers in areas
without adequate screening for G6PD status. Clinicians must ei-
ther chose to give primaquine and risk haemolysis if the patient is
G6PD-deficient, or withhold treatment and accept the complica-
tions of ongoing parasite infection and relapses. This is why when
clinicians choose to treat with primaquine they prefer a lower dose
over a more prolonged period - although this then risks difficulties
with adherence and thus reduced efficacy.
From the previous systematic review on primaquine with chloro-
quine for radical cure (Galappaththy 2013), we know 14 days of
0.25mg/kg or 15mg/day (210mg total dose) is better than shorter
regimens of similar daily doses and placebo. Amajor problem with
the radical cure of P. vivax is difficulty with the adherence of the
14-day course of primaquine, which has led to many countries
shortening the regime. Peru was once such example, although a
study revealed that patients often still discontinued the therapy
after around three days, when they started to feel better (Grietens
2010). A study that compared directly observed therapy (DOT)
for 14 days of primaquine, versus non-DOT primaquine found
that the vivax relapse ratewas significantly lower in theDOTgroup
(Takeuchi 2010). These problems have led to amore urgent call for
shorter treatment regimes. Various trials are investigating regimens
that improves dosing and duration of treatment, to improve ad-
herence and reduce the potential for incomplete treatment and de-
velopment of resistance. As mentioned previously, the significance
of the total cumulative primaquine dose given, rather than length
of course, is one avenue of investigation. In areas where G6PD
screening is present, using higher dosing regimes over shorter time
periods, if at least similarly efficacious, could improve adherence
and reduce morbidity associated with P. vivax parasitaemia.
WHO guidelines suggest a higher dosing regimen of primaquine
for areas with the tropical strain of P. vivax (WHO 2015b), al-
though the previous Cochrane Review, Galappaththy 2013, did
not find any trials that assessed this. Therefore investigating the
evidence base for this is important. The 2015 WHO guidelines
also suggest an alternate dosing regimen of weekly primaquine,
which may be safer in patients with G6PD. In the last Cochrane
Review, only data from one trial assessed this, so it will be useful
to see if there is any further evidence to substantiate this guidance.
In this Cochrane Review, we will exclude comparisons between
blood stage drug (chloroquine/ACT) with and without pri-
maquine as the rationale for primaquine use has been sufficiently
demonstrated in a previous Cochrane Review (Galappaththy
2013). Similarly, we will not include comparisons that look at
different blood stage drugs compared using the same dose of pri-
maquine as an update to an existing Cochrane Review will address
this (Gogtay 2013). However, we will stratify our results according
to partner drug, as there is increasing evidence that primaquine is
metabolized via the CYP2D6 pathway and efficacy may thus be
affected if the blood stage antimalarial drug is a CYP2D6 inhibitor
(Bennett 2013). This review will exclude comparisons of regimens
that do not use the control of 14 days of primaquine at 0.25 mg/
kg/day. Also, it will not include comparisons of primaquine reg-
imens of 0.25 mg/kg daily for less than 14 days as Galappaththy
2013 has already assessed these shorter, same daily dose regimens.
Currently there is a lack of consensus among studies as to what the
minimum time frame for follow-up of relapse in P. vivax malaria
should be. TheWHOguidance on clinical trials inmalaria sets out
standard follow-up for blood (or schizontal) stage infection as 28
days after treatment commencement, but has no clear definition
on the follow-up period for radical cure in primaquine studies. It
states that “follow up varies from three months to a year in the lit-
erature, and should be adapted to regional parasite characteristics”
(WHO 2009). In a recent review, John 2012 described relapse
of the tropical strain of P. vivax as typically three weeks, but this
varies according to blood stage treatment: “three weeks following
quinine therapy” and “six to eight weeks following chloroquine”
(White 2011). With exposure to primaquine - even if radical cure
is not achieved - relapsesmay be at longer intervals (Sutanto 2013).
In the Cochrane Review (Galappaththy 2013), the period of fol-
low-up was 30 days after starting primaquine treatment. Despite
this, the definition of relapse used in the review was the presence
of P. vivax parasites more than 28 to 30 days after the full course of
primaquine in people living in a non-endemic area (Murphy 1993;
Looareesuwan 1997). Because of the varying lengths of relapse
time in P. vivax malaria, as well as the longer schizonticidal half-
life in ACTs, 28 days from treatment commencement may not al-
low true assessment of radical cure. It also makes assessment of the
weekly primaquine regime difficult, as the follow-up time is before
the eight-week treatment course has finished. In this Cochrane
Review we plan to assess parasitaemia at 3, 6, and 12 months fol-
low-up, in keeping with WHO guidance. We intend to describe
the length of follow-up across studies, and then group them into
meaningful lengths of follow-up, depending on the regimen.
We intend to answer the following questions by comparing the
new regimens to the standard regimen of 14 days of primaquine
at 0.25 mg/kg (15 mg adult dose).
• Are higher doses (0.5 mg/kg or 30 mg primaquine/day for
14 days) more efficacious and safe compared to standard therapy
(0.25 mg/kg/day for 14 days), in all areas, or only in areas where
they are standard treatment (for tropical P. vivax strains in Asia,
Pacific)?
• Are shorter, higher dose regimes (0.5 mg/kg or 30 mg
primaquine/day for 7 days) as efficacious and safe compared to
standard therapy (0.25 mg/kg/day for 14 days)?
• Are weekly dosing regimens (0.75 mg/kg or 45 mg/week for
8 weeks) as efficacious and safe compared to standard therapy
(0.25 mg/kg/day for 14 days)?
O B J E C T I V E S
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To assess the efficacy and safety of alternative primaquine regimens
for radical cure ofP. vivax malaria compared to the standard 14
days of primaquine 0.25 mg/kg/day.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCT).Wewill exclude quasi-RCTs.
Types of participants
Adults and children with confirmed clinical and parasitological
(light microscopy or polymerase chain reaction (PCR), or both)
diagnosis of P. vivax malaria. We will include trials that have ex-
cluded people with glucose-6-phosphate-dehydrogenase (G6PD)
deficiency, and trials that included populations that had not been
screened for G6PD deficiency.
Types of interventions
Intervention
Any regimen of either chloroquine or an artemisinin-based com-
bination therapy (ACT) plus primaquine with any of the follow-
ing.
• Higher daily doses for 14 days.
• Shorter regimens with the same total dose.
• Using weekly dosing regimens.
Control
Standard regimen of 14 days of primaquine at 0.25 mg/kg (15 mg
adult dose) plus either chloroquine or an ACT.
Wewill include trials that use chloroquine or ACTas the treatment
for blood-borne infection, andwewill stratify by the schizonticidal
agent.
Types of outcome measures
Primary outcomes
• P. vivax parasitaemia detected (by light microscopy or
polymerase chain reaction (PCR), or both) at 3 months, 6
months, and 12 months follow-up.
Secondary outcomes
• P. vivax parasitaemia detected (by light microscopy or
polymerase chain reaction (PCR), or both) at one to three
months follow-up.
Adverse effects
• Serious adverse effects (fatal, life-threatening, or requiring
hospitalization).
• Adverse effects that result in discontinuation of treatment.
• Events known to occur with primaquine (cyanosis,
leucopenia, methaemoglobinaemia, hypertension, cardiac
arrhythmia, abdominal pain, nausea, vomiting, or haemolysis) or
those due to a comparator drug used along with primaquine.
• Anaemia or change in haemoglobin status.
• Other adverse effects.
Search methods for identification of studies
We will attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, or
in progress).
Electronic searches
We will search the following databases: the Cochrane Infectious
Diseases Group (CIDG) Specialized Register; the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), published in the
Cochrane Library; MEDLINE (PubMed); Embase (OVID); and
LILACS (BIREME), using the search terms detailed in Appendix
1 (Lefebvre 2011). We will also search the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(http://www.who.int/ictrp/search/en/) and ClinicalTrials.gov (
https://clinicaltrials.gov/), to identify ongoing trials, using “vivax”
and “primaquine” as search terms.
Searching other resources
We will check the reference lists of all studies identified by the
above methods for other potentially relevant studies. We will con-
tact researchers working in the field and the World Health Or-
ganization (WHO) for unpublished and ongoing trials. We will
also search the reference lists and included studies of the Cochrane
review by Galappaththy 2013.
Data collection and analysis
Selection of studies
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Two review authors will independently screen the titles and ab-
stracts of the search results to identify potentially eligible trials,
and will code the articles as either ’retrieve’ or ’do not retrieve’. We
will obtain the full-text reports of potentially eligible trials and will
assess them for inclusion in the review using a predesigned eligi-
bility form based on the inclusion criteria. We will resolve discrep-
ancies through discussion or, if required, we will consult a third re-
view author. Where necessary we will contact the trial authors for
clarification of trial methods. We will list the excluded trials and
the reasons for exclusion in a ’Characteristics of excluded studies’
table. Where there are multiple reports relating to the same trial,
we will include all reports. However, we will only extract data from
the most up-to-date report that includes the specified outcome.
We will detail the trial selection process in a PRISMA diagram.
Data extraction and management
Two review authors will independently extract data from the in-
cluded trials using a data extraction form, designed for this review,
in keeping with Cochrane guidance (Higgins 2011).
For each included trial we plan to extract a minimum of the fol-
lowing data if available.
• Study design.
• Endemicity/population demographics.
• G6PD status of participants (known/unknown).
• CYP2D6 status (if available).
• Blood stage antimalarial drug choice.
• Dose/duration/timing of treatment arms.
• Supervised or non-supervised therapy.
• Duration of follow-up.
• Adverse events.
• Reported outcomes.
We will resolve any differences in data extraction through discus-
sion and consult a third review author if there is any discrepancy.
We will enter the extracted data into Review Manager 5 (RevMan
5) (RevMan 2014). We will contact the authors of primary trials
in case of any doubts regarding missing data or methodological
details of the trial. We will note the limitations in the included
studies.
We will group comparisons as illustrated in Table 1.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias of
each included trial using the Cochrane ’Risk of bias’ assessment
tool, and discuss any differences of opinion. In the case of missing
or unclear information, we will contact the trial authors for clar-
ification. We will summarize the results using Cochrane ’Risk of
bias’ tables (Higgins 2011).
Measures of treatment effect
For dichotomous data, we will compare interventions using risk
ratios to measure treatment effect. Where trial authors present
data as odds ratios, we will recalculate the effect. We will define
statistical significance as P < 0.05 and for all resultswewill calculate
95% confidence intervals (CIs). For comparable trials, we will
perform meta-analyses if there is sufficient data.
Unit of analysis issues
For this Cochrane Review, cluster-randomized designs would be
inappropriate for evaluating the research questions. If trials that
have used cluster-randomization meet our inclusion criteria we
would expect the results to have been controlled for clustering.
If they have not, we will contact the trial authors for an estimate
of the intra-cluster correlation coefficient (ICC) value. We will
analyse clustered data using the methods outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will split trials that include more than two comparison groups
and will analyse them as individual pair-wise comparisons. If there
is a shared control group we will split the control group so that
participants are only counted once in the overall meta-analysis.
Dealing with missing data
We will analyse missing data using available case analysis if we
judge the trial to be at low risk of bias for incomplete outcome
data. We will attempt to contact trial authors to obtain missing or
unclear data. If the missing data render the result uninterpretable,
we will exclude the data from meta-analyses and clearly state the
reason for exclusion. If the missing data means that results are
interpretable but likely to be at high risk of bias, we may use
imputation methods to investigate the impact of the missing data.
We will analyse extracted data on an intention-to-treat basis where
there is no missing data.
Assessment of heterogeneity
Wewill inspect forest plots for overlapping CIs.We will also apply
the Chi² test as a statistical test for the presence of heterogeneity,
with a P value of 0.10 used to indicate statistical significance, and
we will compute the I² statistic to quantify the percentage of the
variability in effect estimates that is due to heterogeneity rather
than sampling error (chance). We will investigate possible causes
of heterogeneity by subgroup analysis. If substantive heterogeneity
persists, which we define as an I² statistic value of greater than
50%, we will use a random-effects meta-analysis.
Assessment of reporting biases
Wewill examine the likelihood of reporting bias using funnel plots
provided that there is a sufficient number of included trials.
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Data synthesis
We will analyse the data using Review Manager 5 (RevMan 5)
(RevMan 2014). We will assess the certainty of the evidence
for each outcome measure using the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) ap-
proach and we will construct ’Summary of findings’ tables using
GRADEpro Guideline Development Tool (GDT) (GRADEpro
GDT 2014).We will stratify results according to blood stage part-
ner drug. Length of follow-up will vary with regimes and between
studies. We will describe regimes and follow-up periods and de-
fine sensible groupings for follow-up. If there is sufficient data, we
will also perform subgroup analyses according to CYP2D6 status
(when available), geographical region/endemicity, length of fol-
low-up, and directly observed therapy (DOT) or non-DOT.
Subgroup analysis and investigation of heterogeneity
We will group the analysis by drug regimen. We will describe the
interventions and outcomes in all included trials. We will conduct
an inventory of length of follow-up against each drug regimen and
then group P. vivax parasitaemia relapse by appropriate groupings
for length of follow-up.
Sensitivity analysis
We will assess the risk of bias that contributed data to the meta-
analyses for the prespecified outcomes with sensitivity analyses
against concealment of allocation.
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A D D I T I O N A L T A B L E S
Table 1. Data extraction: Grouping of comparisons to address the review objectives
Objective Intervention Control
Are higher doses more effective (0.5 mg/
kg or 30 mg primaquine/day for 14 days),
in all areas, or only in areas where they are
standard treatment (Asia, Pacific)?
Blood-stage antimalarial drug with pri-
maquine 0.5 mg/kg (30 mg) per day for 14
days (total dose 420 mg)
Both intervention and control groups must
have received the same treatment: either
CQ or ACT for the blood-borne stage of
infection
Blood-stage antimalarial drug with pri-
maquine 0.25 mg/kg (15 mg) per day for
14 days (total dose 210 mg)
Both intervention and control groups must
have received the same treatment: either
CQ or ACT for the blood-borne stage of
infection
Are shorter, higher dose regimes of pri-
maquine over 7 days as effective as treat-
ment over 14 days (is the total dose rather
than the length of treatment the important
factor)?
Blood-stage antimalarial drug with pri-
maquine 0.5 mg/kg (30 mg) per day for 7
days (total dose 210 mg)
Both intervention and control groups must
have received the same treatment: either
CQ or ACT for the blood-borne stage of
infection
Are weekly dosing regimens (0.75 mg/kg
or 45 mg/week for 8 weeks) as effective?
Blood-stage antimalarial drug with pri-
maquine 0.75/kg (45 mg) per week for 8
weeks (total dose 360 mg)
CQ = Chloroquine
ACT = Artemisinin-based combination therapy
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A P P E N D I C E S
Appendix 1. Detailed search strategy
Search set Search terms
1 primaquine [Title/Abstract]
2 “Primaquine”[Mesh]
3 1 or 2
4 “Plasmodium vivax “ [Title/Abstract]
5 “Plasmodium vivax”[Mesh]
6 “vivax malaria ” [Title/Abstract]
7 “Malaria, Vivax”[Mesh]
8 4 or 5 or 6
9 3 and 8
Search terms used in combination with the search strategy for retrieving trials developed by the Cochrane Collaboration (Lefebvre
2011).
This is the preliminary search strategy for MEDLINE (PubMed). We will adapt it for other electronic databases and we will report all
search strategies in full in the final version of the review.
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